Investors may be selling shares of Reviva Pharmaceuticals Holdings, Inc. (RVPH) daily due to several factors, primarily driven by its significant price depreciation, declining institutional interest, and notable short interest.
The stock has experienced a substantial decline, with its share price falling by 45.03% over the past year as of August 6, 2025. This sustained downward trend can lead to continued selling pressure as investors aim to cut losses or reallocate capital.
Institutional ownership in RVPH has also seen a decrease, with a reported 8.25% reduction in institutional shares held in the most recent quarter. This suggests that large, sophisticated investors are reducing their exposure to the company, which can signal a lack of confidence in its near-term prospects.
Furthermore, RVPH has a relatively high short interest, with 10.00% of its float, or 6.05 million shares, being held short. A high short interest indicates that a significant number of market participants are betting against the stock, anticipating further price declines. The "Days to Cover" for RVPH is 5.55 days, suggesting it would take over five trading days for short sellers to cover their positions, which can exacerbate selling pressure during periods of high volume.
Despite these bearish indicators, it's worth noting that the average one-year analyst price target for RVPH is $9.62, significantly higher than its current trading price of $0.45. However, current market sentiment, as reflected in the price action, institutional movements, and short interest, appears to be overriding these long-term analyst projections. Reviva Pharmaceuticals is a clinical-stage company, and its lack of profitability (EPS of -0.62 TTM) may also contribute to investor caution.
